RESUMO
High specific activity (20 Ci/mmol) tritiated hydralazine (3Hyd) distribution in isolated, cultured vascular muscle cells was determined to identify the sites of Hyd binding. 3Hyd dose-dependently bound to extracellular protein and to the area of organelles which secrete these proteins. Increased extracellular binding after Hyd pre-exposure suggests new binding sites may be exacerbated as a result of Hyd interactions. These experiments suggest a potentially important feature of the mechanism of action of this directly acting vasodilator.
Assuntos
Hidralazina/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Animais , Aorta/citologia , Células Cultivadas , Hidralazina/análise , Hidralazina/metabolismo , Microscopia Eletrônica , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/ultraestrutura , Ensaio Radioligante , RatosRESUMO
The vasodilator, hypotensive, and antihypertensive effects of hydralazine and its known and putative metabolites were compared in vitro, in the isolated, perfused mesenteric arterial bed of the rat, and in vivo, in the urethane-anesthetized normotensive rat (NR) and in the conscious renal hypertensive rat (RHR). In the mesenteric bed, hydralazine produced inhibition of noradrenaline (NA)-induced vasoconstriction (IC50-NA = 0.4 micrograms/ml). All the metabolites were five to greater than 250 times less potent than the parent compound. Hydralazine inhibited potassium-induced vasoconstriction at concentrations (IC50-K+ = 700 micrograms/ml) above those required to inhibit NA. Two metabolites, 9-hydroxy-3-methyl-s-triazolo-(3.4-a)phthalazine and the acetone hydrazone (HP-AH), were more potent (five- and 10-fold, respectively) than hydralazine in inhibiting potassium-induced vasoconstriction. The other metabolites produced less than 50% inhibition at the highest concentration tested. In in vivo studies, blood pressure in NR or RHR was reduced by hydralazine, following doses of 0.1 or 0.25 mg/kg i.v. and above. HP-AH was sixfold less active than hydralazine in NR and 10-fold less active in RHR, while the pyruvic acid hydrazone was 33- and 14-fold 1 s active, respectively. The other metabolites tested were practically inactive in concentrations up to the limits of solubility. Although several hydralazine metabolites show some vasodilator and blood pressure-lowering activity, it seems unlikely that the formation of metabolites is a major factor in the antihypertensive effect of hydralazine or is responsible for its long duration of action.
Assuntos
Hidralazina/farmacologia , Animais , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Hidralazina/metabolismo , Hipertensão Renal/tratamento farmacológico , Masculino , Norepinefrina/farmacologia , Potássio/farmacologia , Ratos , Hidróxido de Sódio/farmacologia , Relação Estrutura-Atividade , Uretana , Vasoconstrição/efeitos dos fármacos , Vasodilatação/efeitos dos fármacosAssuntos
Denervação , Rim/inervação , Animais , Cloretos/urina , Rim/metabolismo , Masculino , Nefrectomia , Potássio/urina , Ratos , Ratos Endogâmicos , Renina/sangue , Sódio/urinaAssuntos
Anti-Hipertensivos/toxicidade , Depressores do Sistema Nervoso Central , Hipertensão/tratamento farmacológico , Anestésicos/farmacologia , Animais , Anti-Hipertensivos/administração & dosagem , Comportamento Animal/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Comportamento Exploratório/efeitos dos fármacos , Hipertensão/fisiopatologia , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Fenoxiacetatos/farmacologia , RatosRESUMO
Diclofenac sodium (Voltaren) is a non-steroid anti-inflammatory agent of a new chemical structure, which is animal experiments shows a high degree of anti inflammatory, analgesic, and antipyretic activity in various pharmacological models. It inhibits prostaglandin biosynthesis in vitro and in vivo, and this inhibitory effect at least partly explains the mechanism of action of the preparation. In animal experiments diclofenac sodium is characterised by a broad therapeutic range. Also, its gastrointestinal tolerability is better than that of other highly effective non-steroid anti-inflammatory agents. Two of the metabolites produced during the biotransformation of diclofenac sodium in man are also biologically active. The activity of these two metabolites, however, is very much weaker than that of unchanged diclofenac sodium and is comparable to that of phenylbutazone.